Physician profile
Hala Saad
NPI 1982159612
$2,582.93
in general payments reported to CMS, 2019-2025
28 companies · $723 in 2025
The $723 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $439 · 2022: $380 · 2023: $454 · 2024: $586 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,763.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $423.63 | 2021-2025 | Cabenuva, Dovato, Apretude |
| Amgen INC. | $297.79 | 2021-2023 | Evenity, Prolia |
| Insmed, INC. | $222.26 | 2021-2025 | Arikayce |
| Abbvie INC. | $204.32 | 2022-2025 | Dalvance, Avycaz, Teflaro |
| Harmony Biosciences LLC | $176.72 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $129.91 | 2022-2025 | |
| Inspire Medical Systems, INC. | $115.13 | 2024 | Inspire |
| Aimmune Therapeutics, INC. | $107.16 | 2024-2025 | Vowst, Zenpep |
| Gilead Sciences, INC. | $91.43 | 2023-2025 | Epclusa |
| Shionogi INC | $87.50 | 2022-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $76.87 | 2022-2025 | Nuzyra |
| Esperion Therapeutics, INC. | $74.44 | 2021 | |
| Axsome Therapeutics, INC. | $73.68 | 2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $68.40 | 2024-2025 | Lumryz |
| E.R. Squibb & Sons, L.L.C. | $64.89 | 2021-2023 | Eliquis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $48.87 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $48.22 | 2023-2024 | Vibativ |
| Ferring Pharmaceuticals INC. | $44.26 | 2023-2025 | Rebyota |
| Lilly USA, LLC | $42.71 | 2022 | |
| Novo Nordisk INC | $42.46 | 2021-2025 | Ozempic |
| Welch Allyn | $24.38 | 2021 | |
| Amarin Pharma, INC. | $22.05 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.96 | 2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $18.89 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.06 | 2022 | |
| Daiichi Sankyo INC. | $14.83 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.18 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hala Saad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.